

Paper No. ____
Date Filed: ____

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

AMERIGEN PHARMACEUTICALS LIMITED
Petitioner,

v.

JANSSEN ONCOLOGY, INC.
Patent Owner.

Case IPR2016-00286
Patent 8,822,438 B2

**DECLARATION OF S. ISAAC OLSON IN
SUPPORT OF MOTION TO APPEAR *PRO HAC VICE***

I, S. Isaac Olson, declare as follows:

1. I am counsel in the New York Office of Sidley Austin LLP. I have personal knowledge of the facts set forth in this declaration and, if called as a witness, could and would testify competently under oath.

2. I am a member in good standing of the State Bar of New York (Bar No. 4625190).

3. I have never been suspended or disbarred from practice before any court or administrative body.

4. None of my applications for admission to practice before any court or administrative body have ever been denied.

5. I have not been sanctioned nor have I had a contempt citation imposed on me by any court or administrative body.

6. I have read and will comply with the Office Patent Trial Practice Guide and the Board's Rules of Practice for Trial set forth in part 42 of 37 C.F.R.

7. I acknowledge and agree that I will be subject to the USPTO Rules of Professional Conduct set forth in 37 C.F.R. § 11.101 *et. seq.* and disciplinary jurisdiction under 37 C.F.R. § 11.19(a).

8. I have not applied to appear *pro hac vice* before the Patent Trial and Appeal Board in the last three years.

IPR2016-00286
Patent No. 8,822,438

9. I have been a practicing attorney for almost nine years and have been involved in numerous patent cases. I am presently counsel for Patent Owner Janssen Oncology, Inc. in two pending patent litigations¹ involving the patent under review in this proceeding, U.S. Patent No. 8,822,438 (the “‘438 patent”). As part of these litigations, I have studied and analyzed the ‘438 patent and have become very familiar with its subject matter. I have also gained familiarity with certain prior art (including prior art asserted in this IPR proceeding), conception and reduction to practice of the inventions claimed in the ‘438 patent, and other relevant issues, including claim construction of various claim terms.

I declare under penalty of perjury that the foregoing is true and correct.

Executed on August 19, 2016 in New York, New York

By: 
S. Isaac Olson

¹ *BTG Int’l Ltd., et al., v. Actavis Labs. FL, Inc., et al.*, C.A. No. 2:15-cv-05909-KM-JBC (D.N.J.) and *Janssen Biotech, Inc., et al., v. Mylan Pharm. Inc., et al.*, C.A. No. 1:15-cv-00130-IMK (N.D. W. Va.).